Clinical trials: Experimental
Healthy
Data Acquisition to Model Glycemic Response
To learn about individual glycemic response to physiological and psychological conditions across a diverse population, the investigators will collect sensor and lifestyle data directly from participants as they engage in daily…
- Trial name
- SDI (NCT03612999)
- Testing
- Dexcom continuous glucose monitor, Fitbit activity tracker, Subjects record daily activity
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Savvysherpa, Inc.
NSCLC, Adjuvant Drug Therapy
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations.
- Conditions
- NSCLC, Adjuvant Drug Therapy, EGFR
- Trial name
- NCT07181499
- Testing
- Befotertinib, Pemetrexed + Carboplatin
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Gingivitis, Plaque, Dental
Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash
Qualified subjects will be enrolled and randomized to either one of the two study groups described above based on their initial modified gingivitis and plaque scores.
- Trial name
- NCT07263698
- Testing
- cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash, sodium fluoride Mouthwash
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Depression, Anxiety
Effects of Probiotics on Mood
Recent demonstration that probiotics administration has positive effects on depressive feelings in healthy populations suggests its possible role as an adjuvant therapy for depression in clinical populations and as a non-invasive…
- Trial name
- NCT03539263
- Testing
- Bifihappy
- Where
- Italy
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Probiotical S.p.A.
Solid Tumor, Adult
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the treatment of solid tumors through…
- Trial name
- NCT05388487
- Testing
- HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m²
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- HighField Biopharmaceuticals Corporation
Infection, Human Immunodeficiency Virus
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
In this study, approximately 16 subjects will receive raltegravir 400mg twice daily for 5 days (Treatment A) followed by a washout period. In Period 2, subjects will receive GSK2248761 200mg once daily for 5 days (Treatment B).
- Trial name
- NCT01101893
- Testing
- Raltegravir, GSK2248761, GSK2248761 + Raltegravir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cocaine Use, Cocaine Intoxication
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department…
- Conditions
- Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse
- Trial name
- CATALYST (NCT06045793)
- Testing
- TNX-1300 (Injection)
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
- Trial name
- P2_ABSSSI (NCT03964493)
- Testing
- TNP-2092, Vancomycin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- TenNor Therapeutics Limited
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Constriction, Pathologic
FLAIR™ Delivery System Study
The objective of this clinical study is to evaluate the performance of the Optimized FLAIR™ Delivery System.
- Trial name
- FLAIR DS (NCT00614315)
- Testing
- FLAIR™ Endovascular Stent Graft
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- C. R. Bard
Niemann-Pick Type C Disease, GM1 Gangliosidosis
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in…
- Conditions
- Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
- Trial name
- NCT07054515
- Testing
- AZ-3102
- Where
- 39 sites in United States, Argentina and 15 more
- Volunteers
- 147 people
- Sponsor
- Azafaros B.V.
Glaucoma, Ocular Hypertension
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT01693315
- Testing
- AMA0076
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Amakem, NV
Asthma
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
- Trial name
- CONTROL (NCT01225315)
- Testing
- Setipiprant
- Where
- 97 sites in United States, Australia and 11 more
- Volunteers
- 438 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Atrial Fibrillation
Effect of Diltiazem on Pharmacokinetics of BMS-914392
The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.
- Trial name
- NCT01211808
- Testing
- BMS-914832, Diltiazem
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Visual Acuity
2-week Evaluation of Marketed Silicone Hydrogel Contact Lenses in Indian Population
The primary objective of this study is to evaluate the clinical performance of two marketed silicone hydrogel contact lenses in an Indian population in the following areas: physiological characteristics, comfort characteristics…
- Trial name
- NCT02394808
- Testing
- senofilcon A, lotrafilcon B
- Where
- India
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Healthy Participants
A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants
A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.
- Trial name
- NCT04175925
- Testing
- BMS-986322, famotidine
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitis Type 2
A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects
This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic…
- Trial name
- NCT00961025
- Testing
- DA-1229
- Where
- South Korea
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
- Trial name
- PROVENT (NCT04625725)
- Testing
- AZD7442
- Where
- 89 sites in United States, Belgium and 3 more
- Volunteers
- 5,197 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate)
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease.
- Conditions
- Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
- Trial name
- NCT03795389
- Testing
- DM199
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- DiaMedica Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.